Theranostic applications of lutetium-177 in radionuclide therapy

Current Radiopharmaceuticals

Volumn 9, Issue 1, 2016, Pages 94-101

  Das, Tapas ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; Metastatic bone pain palliation; Peptide receptor radionuclide therapy; Pharmacokinetic mapping; Theranostic applications

Indexed keywords

HYDROXYAPATITE; LUTETIUM 177; MEDRONATE TECHNETIUM TC 99M; RADIOISOTOPE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; OCTREOTIDE; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ARTICLE; BODY IMAGE; BONE PAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; NEUTRON RADIATION; PALLIATIVE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; RADIOCHEMISTRY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYNOVECTOMY; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; COMPARATIVE STUDY; HALF LIFE TIME; METABOLISM; PAIN; PROCEDURES; SECONDARY; THERANOSTIC NANOMEDICINE;

BONE NEOPLASMS; DURAPATITE; HALF-LIFE; HUMANS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; THERANOSTIC NANOMEDICINE;

EID: 84949870910     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150313114644     Document Type: Article

References (32)

1. Kelkar, S.S.; Reineke, T.M. Theranostics: Combining imaging and therapy. Bioconj. Chem., 2011, 22, 1879-1903.
2. Wang, P.; Moore, A. Theranostic magnetic resonance imaging of type 1 diabetes and pancreatic islet transplantation. Quant. Imaging Med. Surg., 2012, 2, 151-162.
3. DeNardo, G.L; Denardo, S.J. Concept, consequences, and implications of theranosis. Semin. Nucl. Med., 2012, 42, 147-150.
4. Srivastava, S.C. Paving the way to personalized medicine: Production of some promising theragnostic radionuclides at Brookhaven National Laboratory. Semin. Nucl. Med., 2012, 42, 151-163.
5. Baum, R.P.; Kulkarni, H.R. Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience. Theranostics, 2012, 2, 437-447.
6. Pillai, M.R.A.; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59, 109-118.
7. Das, T.; Pillai, M.R.A. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl. Med. Biol., 2013, 40, 23-32.
8. Shinto, A.S.; Shibu, D.; Kamaleshwaran, K.K.; Das, T.; Chakraborty, S.; Banerjee, S.; Thirumalaisamy, P.; Das, P.; Veersekar, G. 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J. Nucl. Med. Technol., 2014, 42, 55-61.
9. Solá, G.A.R.; Argüelles, M.G.; Bottazzini, D.L.; Furnari, J.C.; Parada, I.G.; Rojo, A.; Ruiz, H.V. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies. Radiochim. Acta, 2000, 88, 157-162.
10. Das, T.; Bhadwal, M.; Banerjee, S.; Sarma, H.D.; Shinto, A.; Kamaleshwaran, K.K. Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. J. Radioanal. Nucl. Chem., 2014, 299, 1389-1398.
11. Chakraborty, S.; Das, T.; Banerjee, S.; Balogh, L.; Chaudhari, P.R.; Sarma, H.D.; Polyák, A.; Máthé, D.; Venkatesh, M.; Janoki, G.A.; Pillai, M.R.A. 177Lu-EDTMP : A viable bone pain palliative in skeletal metastasis. Cancer Biother. Radiopharm., 2008, 23, 202-213.
12. Das, T.; Chakraborty, S.; Sarma, H.D.; Banerjee, S.; Venkatesh, M. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy. Nucl. Med. Biol., 2010, 37, 655-663.
13. Banerjee, S.; Das, T.; Chakraborty, S.; Venkatesh, M. Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. Radiochim. Acta, 2012, 100, 115-126.
14. Máthé, D.; Balogh, L.; Polyák, A.; Király, R.; Márián, T.; Pawlak, D.; Zaknun, J.J.; Pillai, M.R.A.; Jánoki, G. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl. Med. Biol., 2010, 37, 215-226.
15. Sola, G.A.R.; Arguelles, M.G.; Bottazzini, D.L.; Furnari, J.C.; Parada, I.G.; Rojo, A.; Vera Ruiz, H. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim. Acta, 2000, 88, 157-161.
16. Ando, A.; Ando, I.; Tonami, N.; Kinuya, S.; Kazuma, K.; Kataiwa, A.; Nakagawa, M.; Fujita, N. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl. Med. Commun., 1998, 19, 587-591.
17. Fellner, M.; Baum, R.; Kubicek, V.; Hermann, P; Roesch, F. 177Lu-BPAMD-From bone imaging to therapy with a macrocyclebisphosphonate ligand. J. Nucl. Med., 2010, 51(Suppl. 2), 1164.
18. Shultz, M.D.; Wilson, J.D.; Fuller, C.E.; Zhang, J.; Dorn, H.C.; Fatouros, P.P. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology, 2011, 261, 136-143.
19. Chakraborty, S.; Das, T.; Banerjee, S.; Sarma, H.D.; Venkatesh, M. Preparation and preliminary biological evaluation of 177Lu labeled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl. Med. Commun., 2006, 27, 661-668.
20. Chakraborty, S.; Das, T.; Sarma, H.D.; Venkatesh, M.; Banerjee, S. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in therapy of liver cancer. Nucl. Med. Biol., 2008, 35, 589-597.
21. Unni, P.R.; Chaudhari, P.R.; Venkatesh, M.; Ramamoorthy, N.; Pillai, M.R.A. Preparation and bioevaluation of 166Ho labeled hydroxyapatite (HA) particles for radiosynovectomy. Nucl. Med. Biol., 2002, 29, 199-209.
22. Available from: http://www.britatom.gov.in/docs/rph_ria_cat/RPH_COLD/RPH_TCK30.pdf
23. [Accessed Oct 20, 2014].
24. Basu, S.; Kand, P.; Mallia, M.; Korde, A.; Shimpi, H. Gratifying clinical experience with an indigenously formulated single-vial lyophilized HYNIC-TOC kit at the Radiopharmaceutical Division of BARC: A pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 1622-1624.
25. Das, T.; Chakraborty, S.; Kallur, K.G.; Venkatesh, M.; Banerjee, S. Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: The Indian experience. Cancer Biother. Radiopharm., 2011, 26, 395-400.
26. Danthala, M.; Kallur, K.G.; Prashant, G.R.; Rajkumar, K.; Rao, M.R. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India. Eur. J. Nucl. Med. Mol. Imaging, 2014, (In-Press) DOI: 10.1007/s00259-014-2710-1.
27. Yuan J.; Liu, C.; Liu, X.; Wang, Y.; Kuai, D.; Zhang, G.; Zaknun J. J. Efficacy and Safety of 177Lu-EDTMP in Bone Metastatic Pain Palliation in Breast Cancer and Hormone Refractory Prostate Cancer: A Phase II Study. Clin. Nucl. Med., 2013; 38, 88-92.
28. Das, T.; Chakraborty, S.; Banerjee, S.; Nair, K.V.V.; Chirayil, V.; Venkatesh, M.; Sarma, H.D.; Bal, C.S.; Arora, G. 177Lu-EDTMP: A new radiopharmaceutical for palliation of bone pain in cancer patients with skeletal metastases. BARC Newsletter, 2009, 305, 2-11.
29. Singh, N.; Krishna, B.A.; Vyas, M.; Venkatesh, M.; Banerjee, S.; Das, T.; Nair, K.V.V.; Chakraborty, S. Lutetium DOTATATE whole body scans-A novel approach for evaluation of neuroendocrine tumors. Ind. J. Nucl. Med., 2011, 26, 135-138.
30. Virgolini, I., Ambrosini, V., Bomanji, J.B., Baum, R.P., Fanti, S., Gabriel, M., Papathanasiou, N.D., Pepe, G., Oyen, W., De Cristoforo, C., Chiti, A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 2004-2010.
31. Ambrosini, V., Campana, D., Tomassetti, P., Fanti, S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39 (Suppl. 1), S52-S60.
32. Maecke, H.R., Hofmann, M., Haberkorn, U. 68Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005, 46(Suppl. 1), 172S-178S.